S 838
107th Congress
Senate
Health
Administrative procedure
Administrative remedies
Bioethics
Cancer
Chemotherapy
Child health
Clinical trials
Commerce
Congress
Congressional reporting requirements
Department of Health and Human Services
Drug adulteration
Drug approvals
Drug industry
Drug therapy
Economic impact statements
Economics and Public Finance
Executive reorganization
Families
Best Pharmaceuticals for Children Act
Introduced: May 7, 2001
See on congress.gov
Everywhere this bill has been
13 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 23, 2001
Message on Senate action sent to the House.
Oct 23, 2001
Received in the House.
Oct 23, 2001
Held at the desk.
Oct 18, 2001
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Oct 18, 2001
The committee substitute as amended agreed to by Unanimous Consent.
Oct 18, 2001
Measure laid before Senate by unanimous consent. (consideration: CR S10816-10819; text of measure as reported: CR S10816-10818)
Oct 18, 2001
Passed Senate with an amendment by Unanimous Consent.
Oct 4, 2001
Committee on Health, Education, Labor, and Pensions. Reported by Senator Kennedy with an amendment in the nature of a substitute. With written report No. 107-79.
Oct 4, 2001
Placed on Senate Legislative Calendar under General Orders. Calendar No. 184.
Aug 1, 2001
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
May 7, 2001
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S4422-4424)
May 7, 2001
Sponsor introductory remarks on measure. (CR S4422)
May 7, 2001
Introduced in Senate
Plain-English summary
Best Pharmaceuticals for Children Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services, through the National Institutes of Health, to develop a list of approved drugs for which: (1) there is no patient or market exclusivity protection; and (2) additional pediatric safety and effectiveness studies are needed. Directs the Secretary to award contracts to entities with appropriate experience for pediatric clinical trials of such drugs.
Establishes a Food and Drug Administration (FDA) contract process for related labeling changes.
Amends the Federal Food, Drug, and Cosmetic Act to: (1) eliminate the user fee waiver for pediatric supplements to a human drug application; (2) provide priority status for pediatric supplements; (3) include neonates within the definition of pediatric studies; (4) provide for dissemination of pediatric supplement information; and (5) set forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs.
Directs the Secretary to establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities.
What's happening now
Held at the desk.
Committees of jurisdiction
1